BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 38195781)

  • 21. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.
    Tang L; Huang Z; Mei H; Hu Y
    Signal Transduct Target Ther; 2023 Aug; 8(1):306. PubMed ID: 37591844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Personalized Immuno-Oncology.
    Jain KK
    Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
    Pennock GK; Chow LQ
    Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome Prediction and Evaluation by Imaging the Key Elements of Therapeutic Responses to Cancer Immunotherapies Using PET.
    Bu L; Sun Y; Han G; Tu N; Xiao J; Wang Q
    Curr Pharm Des; 2020; 26(6):675-687. PubMed ID: 31465273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
    Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
    J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era.
    Klener P; Etrych T; Klener P
    Curr Med Chem; 2019; 26(6):1002-1018. PubMed ID: 28990505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Advances in Immunotherapies for Hematological Malignancies.
    Nogami A; Sasaki K
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recent advances and future challenges in cancer immunotherapy].
    Okuyama N; Tamada K; Tamura H
    Rinsho Ketsueki; 2016; 57(11):2388-2395. PubMed ID: 27941290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical cancer immunotherapy: Current progress and prospects.
    Liu C; Yang M; Zhang D; Chen M; Zhu D
    Front Immunol; 2022; 13():961805. PubMed ID: 36304470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
    Ni K; Luo T; Nash GT; Lin W
    Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics.
    Abaza A; Sid Idris F; Anis Shaikh H; Vahora I; Moparthi KP; Al Rushaidi MT; Muddam MR; Obajeun OA; Jaramillo AP; Khan S
    Cureus; 2023 Sep; 15(9):e44582. PubMed ID: 37667784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma.
    Liu X; Zhao Z; Dai W; Liao K; Sun Q; Chen D; Pan X; Feng L; Ding Y; Wei S
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives.
    Koustas E; Trifylli EM; Sarantis P; Papadopoulos N; Karapedi E; Aloizos G; Damaskos C; Garmpis N; Garmpi A; Papavassiliou KA; Karamouzis MV; Papavassiliou AG
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy as an Option for Cancer Treatment.
    Rusch T; Bayry J; Werner J; Shevchenko I; Bazhin AV
    Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):89-96. PubMed ID: 29026920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune escape mechanisms and immunotherapy of urothelial bladder cancer.
    Yang Z; Xu Y; Bi Y; Zhang N; Wang H; Xing T; Bai S; Shen Z; Naz F; Zhang Z; Yin L; Shi M; Wang L; Wang L; Wang S; Xu L; Su X; Wu S; Yu C
    J Clin Transl Res; 2021 Aug; 7(4):485-500. PubMed ID: 34541363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing Cancer Chemo-Immunotherapy: Innovative Approaches for Overcoming Immunosuppression by Functional Nanomaterials.
    Wang J; Li L; Xu ZP
    Small Methods; 2024 Jan; 8(1):e2301005. PubMed ID: 37743260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapeutic Agents for Intratumoral Immunotherapy.
    Shyr CR; Liu LC; Chien HS; Huang CP
    Vaccines (Basel); 2023 Nov; 11(11):. PubMed ID: 38006049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.